CD274 and hepatocellular carcinoma: Although several PD-1/PD-L1 and antiangiogenic combinations have been approved as first-line treatments, unmet needs persist due to the high morbidity and mortality of HCC, along with regional approval status, reimbursement restrictions, and cost considerations (12).